ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention

Atherosclerosis

Volumn 201, Issue 1, 2008, Pages 148-154

  Shah, Svati H ^a   Hauser, Elizabeth R ^a   Crosslin, David ^a   Wang, Liyong ^a   Haynes, Carol ^a   Connelly, Jessica ^a   Nelson, Sarah ^a   Johnson, Jessica ^a   Gadson, Shera ^a   Nelson, Charlotte L ^a   Seo, David ^b   Gregory, Simon ^a   Kraus, William E ^a   Granger, Christopher B ^a   Goldschmidt Clermont, Pascal ^b   Newby, L Kristin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Genetics; Inflammation; Stent restenosis

Indexed keywords

LEUKOTRIENE;

ADULT; ALOX5AP GENE; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; IN-STENT RESTENOSIS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARRIER PROTEINS; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GENETIC ASSOCIATION STUDIES; GRAFT OCCLUSION, VASCULAR; HAPLOTYPES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 53849085513     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.01.011     Document Type: Article

References (25)

1. Lowe H.C., Oesterle S.N., and Khachigian L.M. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 39 (2002) 183-193
2. Kastrati A., Schomig A., Elezi S., et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30 (1997) 1428-1436
3. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
4. Holmes Jr. D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
5. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
6. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
7. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
8. Kong D.F., and Eisenstein E.L. Decision models for assessing the cost effectiveness of drug-eluting stents. Expert Opin Pharmacother 6 (2005) 965-974
9. Seo D., Wang T., Dressman H., et al. Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 1922-1927
10. Karra R., Vemullapalli S., Dong C.M., et al. Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A 102 (2005) 16789-16794
11. Smith L.R., Harrell Jr. F.E., Rankin J.S., et al. Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. Circulation 84 (1991) III245-III253
12. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
13. Helgadottir A., Manolescu A., Helgason A., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction 1. Nat Genet 38 (2006) 68-74
14. Agema W.R., Jukema J.W., Zwinderman A.H., et al. A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J 144 (2002) 760-768
15. Gomma A.H., Elrayess M.A., Knight C.J., et al. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 23 (2002) 1955-1962
16. Humphries S., Bauters C., Meirhaeghe A., et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J 23 (2002) 721-725
17. Koch W., Bottiger C., Mehilli J., et al. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am J Cardiol 88 (2001) 1120-1124
18. Rauchhaus M., Gross M., Schulz S., et al. The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty. Int J Cardiol 83 (2002) 249-257
19. Ohtani K., Egashira K., Nakano K., et al. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation 114 (2006) 2773-2779
20. Komatsu H., Kojima M., Tsutsumi N., et al. Mechanism of inhibitory action of tranilast on the release of slow reacting substance of anaphylaxis (SRS-A) in vitro: effect of tranilast on the release of arachidonic acid and its metabolites. Jpn J Pharmacol 46 (1988) 53-60
21. Capper E.A., Roshak A.K., Bolognese B.J., et al. Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis. J Pharmacol Exp Ther 295 (2000) 1061-1069
22. Fukuyama J., Ichikawa K., Miyazawa K., et al. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol 70 (1996) 321-327
23. Hsu Y.S., Tamai H., and Lleda K. Efficacy of tranilast on restenosis after coronary stenting. Circulation 94 (1996) I-620
24. Holmes Jr. D.R., Savage M., Lablanche J.M., et al. Results of prevention of REStenosis with tranilast and its outcomes (PRESTO) trial. Circulation 106 (2002) 1243-1250
25. DeChiara T.M., Kimble R.B., Poueymirou W.T., et al. Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet 24 (2000) 271-274